Phase II clinical study in patients with Parkinson's disease taking L-DOPA
Phase 2
- Conditions
- Parkinson's disease
- Registration Number
- JPRN-jRCT2080221835
- Lead Sponsor
- Hisamitsu Pharmaceutical Co.,Inc.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Patients diagnosed with Parkinson's disease in stages 2 to 4 on the modified Hoehn & Yahr scale
Exclusion Criteria
- Patients with history of hypersensitivity to ropinirole
- Patients with clinically significant renal impairment or hepatic dysfunction
- Patients who have cutaneous abnormality at planned application site that can be worsen by application with investigational product
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Efficacy
- Secondary Outcome Measures
Name Time Method Safety